Teva Pharmaceutical Industries Ltd. announced the FOCUS (Phase IIIb Study of Fremanezumab) exploratory endpoints results at the 5th Congress of the European Academy of Neurology.
The first timed shared endpoints at EAN concluded the presentation of endpoints which were pre-specified from the Phase IIIb FOCUS study. This study accessed the efficacy and safety of Fremanezumab for the prevention treatment of migraine in adult patients who previously experienced inadequate responses to two to four classes of these treatments.
These results showed abatement in monthly average migraine days; cutback in migraine related symptoms; and progression in depression status; work productivity and activity impairment.
Migraine is a neurological disease which is disabling and is characterized by acute head pain, nausea and vomiting. It is the second leading cause of years lived with disability worldwide with profound brunt on patients, their friends and family, and on society as a whole. FOCUS study data unveiled the Fremanezumab results on a range of quality of life and disability measures as well as showing a significant abatement in the number of hours of headache and suffering days by patients and on a spectrum of associated symptoms.
Clinical Research Newsletter
Mr Vinod Arora, Principal Advisor, IGMPI
Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like